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“We all make mistakes, and it is better to make them before we begin.” 
                       Nikola Tesla 
 
  
ABSTRACT 
Polycystic ovary syndrome (PCOS) is the most common endocrine and 
metabolic disorder in women. Women with PCOS demonstrate metabolic 
morbidities such as obesity, insulin resistance with compensatory 
hyperinsulinemia and type 2 diabetes.  Physical inactivity in women with 
PCOS aggravates the metabolic conditions. Pharmacological treatment is 
efficient but associated with side effects. The pathogenesis of PCOS is largely 
unknown and current research suggests that genetic and epigenetic factors are 
implicated. Epigenetics e.g. methylation is an important mechanism that 
regulates gene transcription and transcriptional alterations could explain 
metabolic aberrations associated with PCOS.  
The aim of this thesis was to profile genome-wide gene expression and 
methylation patterns in adipose tissue and skeletal muscle in women with 
PCOS and controls, and to investigate if electroacupuncture could be used to 
restore altered CpG sites and transcriptional alterations. Furthermore, we 
aimed to investigate the effect and mechanisms of a single bout of low-
frequency electroacupuncture (EA) on whole-body glucose uptake. 
The results of the thesis demonstrate that women with PCOS have multiple 
differentially methylated sites that are associated to gene expression changes 
in adipose tissue. In subcutaneous adipose tissue, we found 30 differentially 
methylated genes that are associated with mRNA expression. We have shown 
that transcriptional alteration in adipose tissue are associated to circulating 
testosterone, glucose infusion rate and adipocyte size. Furthermore, in adipose 
tissue electroacupuncture reversed expression of 80 genes to a healthier 
phenotype. In skeletal muscle, we found 85 genome-wide transcriptional 
differences and 21 differentially methylated genes. We also showed that 
mRNA expression levels of KLF10 and COL1A1 are under hormonal 
regulation of insulin and testosterone respectively and both of these genes are 
involved in controlling glycogen accumulation in human skeletal muscle cells.  
Women with PCOS have increased sympathetic nerve activity, which is related 
to aberrant androgen levels and this can lead to increased insulin resistance and 
obesity. We have shown that EA lowers protein expression of markers of 
sympathetic nerve activity: proNGF, serotonin and homovanillic acid in 
adipose tissue. We measured whole-body glucose uptake by euglycemic-
hyperinslinemic clamp and we demonstrated that EA increases glucose 
infusion rate in both rats and in women with PCOS and controls. In the rat 
experiment, we show that administration of α and β blockers during clamp 
blocks glucose uptake suggesting that adrenergic receptors partly mediates the 
effect of EA by activating the autonomic nervous system. Overall, EA-induced 
glucose uptake was controlled by activation of both sympathetic and 
parasympathetic nervous system in rats. In women with PCOS we identified 
increased expression of several genes involved in regulation of glucose uptake, 
including NR4A2 and JUNB, in adipose tissue after EA. We investigated 
transcriptional changes of those genes in rats receiving α and β adrenergic 
blockers, and the involvement of the sympathetic nervous system is supported 
by lowered expression of Nr4a2 and Junb genes, suggesting that EA mediates 
it effect by affecting mRNA levels of those genes.   
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ISBN: 978-91-629-0381-7 (PDF)  
POPULÄRVETENSKAPLIG SAMMANFATTNING  
Polycystiskt ovariesyndrom (PCOS) är en vanlig hormonell och metabol 
störning som förekommer hos  ungefär 17 % av alla kvinnor i fertil ålder. 
Syndromet leder till ökning av det manliga könshormonet testosteron, ökad 
kroppsbehåring, akne och oregelbunden menstruation, vilket leder till nedsatt 
fertilitet. Många kvinnor med PCOS är överviktiga och har nedsatt 
insulinkänslighet vilket ofta leder till typ 2-diabetes. Det är okänt vad som 
orsakar PCOS men miljö, epigenetiska och genetiska faktorer har en inverkan. 
Epigenetik syftar på förändringarna som sker på DNAt utan att underliggande 
mekanismer påverkas. Epigenetiska mekanismer kontrollerar hur DNA läses 
av och hur generna uttrycks. Det finns olika epigenetiska mekanismer som 
DNA-metylering, histonmodifiering och icke-kodande RNA som reglerar 
genuttryck. Epigenetik är ett relativt nytt forskningsområde som kan vara 
involverat i utvecklingen av PCOS.  
Målet med denna avhandling var att undersöka om det finns 
metyleringsförändringar som påverkar genuttryck i fettvävnad och 
skelettmuskulatur och som därmed kan förklara metabola störningar hos 
kvinnor med PCOS. Vi undersökte också om akupunktur i kombination med 
elektrisk stimulering av nålarna,  s.k. elektroakupunktur (EA), kan öka 
glukosupptag och insulinokänslighet hos överviktiga och obesa kvinnor, samt 
om epigenetiska förändringar kan återställas av akupunktur.   
Vi fann att kvinnor med PCOS har epigenetiska förändringar som kan påverka 
ett stort antal gener som är relevanta för utvecklingen av PCOS i både i 
fettvävnad och skelettmuskulatur. I fettväv hittades 30 och i skelettmuskel 21 
gener som var skilda i både metylering och genuttryck och som kunde 
associeras till kliniska PCOS-karakteristika. En gen som regleras av insulin 
(KLF10) ökade i expressionen i både muskel och fett i kvinnor med PCOS, och 
det kan leda till både lägre glukosupptaget och insulinkänsliget.  
Lågfrekvent elektroakupunktur under 45 minuter ökade glukosupptaget hos 
både friska kontroller och kvinnor med PCOS. Samtidigt återställdes DNA-
metylering och genuttryck så att det till stor del liknade det som ses hos friska 
kontroller. Effekterna av elektroakupunktur förmedlades (åtminstone delvis) 
av det autonoma nervsystemet eftersom effekterna blockerades när ett 
läkemedel som blockerar sympatikus och parasympatikus administrerades till 
råttor. Hos kvinnor med PCOS har vi dessutom identifierat ökat genuttryck i 
NR4A2 och JUNB och ökat glukosupptag efter efter 45 minuters behandling 
med elektroakupunktur. I råttor har vi undersökt hur genuttrycket förändras när 
råttorna fick sympatikus- och parasympatikusblockare. Vi fann att 
genuttrycket av Nr4a2 och Junb sänktes i gruppen som fick sympatikus- och 
parasympatikusblockare, vilket tyder på att elektroakupunktur medierar 
effekten genom att påverka mRNA-nivåer av dessa två gener. NR4A2 och 
JUNB är transkritionsfaktorer som är kopplade till inflammatoriska respektive 
metabola störningar. Ytterligare stöd för att effekten av elektroakupunktur 
förmedlas via modulering av autonom aktivitet stöds av fynden att 
proteinuttrycket av nervtillväxtfaktorn (NGF), en markör för 
sympatikusaktivitet, efter 45 minuters behandling med elektroakupunktur hade 
minskat hos kvinnor både med och utan PCOS.  
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1 INTRODUCTION 
1.1 POLYCYSTIC OVARY SYNDROME 
Polycystic ovary syndrome (PCOS) is a complex endocrine and metabolic 
disorder that affects between 5−17% of women worldwide (1, 2). The 
aetiology of PCOS is poorly understood and high prevalence might be due to 
the genetic predisposition, environmental and epigenetic factors (3). Up to 
70% can be attributed to heredity and genetic factors. Recent genome wide 
association studies (GWAS) have identified around 15 to 19 susceptible genes, 
which may be involved in the development of PCOS (4, 5).   
1.2 DIAGNOSIS AND PREVALENCE 
Diagnostic criteria of PCOS are under debate. According to the National 
Institute of Health (NIH) requirement for diagnosis of PCOS are 
hyperandrogenism and ovulatory dysfunctions (6). European Society for 
Human Reproduction and Embryology and American Society for 
Reproductive Medicine require the presence of at least two out of three 
following: hyperandrogenism, ovulatory dysfunction and/or PCO morphology 
(7), and Androgen Excess and PCOS Society require presence of 
hyperandrogenism and ovarian dysfunction or PCO morphology (8). In the 
Rotterdam Consensus report from 2003 (7) PCO morphology was included in 
the diagnostic criteria which have resulted in more phenotypes (9) (Table 1). 
Table 1. Diagnostic criteria in PCOS  
Identification of specific phenotypes includes: 1: HA + OD + PCOM; 2: HA + OD; 3: HA + 
PCOM; 4: OD + PCOM. Hyperandrogenism; HA, ovulatory dysfunctions; OD, PCO 
morphology; PCOM. 
NIH 1990 Rotterdam 2003 AE-PCOS 2006 
HA 
OD 
HA 
OD 
PCOM 
           HA 
OD and/or PCOM 
Both criteria needed Two out of three criteria 
needed 
Both criteria needed 
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1.3 PATHOPHYSIOLOGY 
The pathogenesis of PCOS is complex and not elucidated. The hallmarks of 
PCOS are hyperandrogenemia and hyperinsulinemia. The hyperandrogenemia, 
is a direct result of excessive androgen production from the theca cells in the 
ovaries and to a small extent production from the adrenal gland (10). Women 
with PCOS have impaired steroidogenesis, P450 aromatase activity in thecal 
cells is decreased contributing to high levels of androgens and increased 
CYP17 activity (11). It is not understood if hypersecretion of androgens from 
the ovaries starts the early age or at the puberty (12). However, there are 
convincing evidence that foetal hyperandrogenisation in utero might lead to 
epigenetic reprogramming in foetal reproductive tissue which in adulthood 
leads to development of PCOS (13). Furthermore, excessive androgen 
exposure during foetal life may contribute to development of insulin resistance 
and visceral adiposity (14). Insulin resistance with compensatory 
hyperinsulinemia controls availability of androgens where hyperinsulinemia 
leads to decreased secretion of sex hormone binding globulin (SHBG) from 
the liver which subsequently leads to increased levels of circulating free 
androgens (15). Moreover, increased levels of free androgens in the circulation 
affect insulin action in both skeletal muscle and adipose tissue (16).  
Women with PCOS exhibit neuroendocrine defects where increased ovarian 
androgen production is, in part, a result of increased ratio between luteinizing 
hormone (LH) and follicle stimulating hormone (FSH) (17) resulting with 
elevated LH/FSH ratio. Gonadotropin releasing hormone (GnRH) plays an 
essential role in pathogenesis of the PCOS where, either increased pituitary 
sensitivity to GnRH or increased pulse frequency of GnRH secretions leads to 
aberrant secretion of gonadotropins (18). In addition, it is common that women 
with PCOS are overweight or obese which leads to aggravation of other PCOS 
symptoms (19) (Figure 1).  
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Figure 1. Hypothetical model of the pathophysiology of PCOS includes: 
Genetic and epigenetic defects, excessive ovarian and adrenal steroidogenesis, 
neuroendocrine defects, increased sympathetic activity, metabolic disturbances, 
insulin resistance with compensatory hyperinsulinemia and overweight/obesity. 
Illustration by Igor Cervenka 
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1.4 METABOLIC DYSFUNCTION IN PCOS 
1.4.1 Adipose tissue 
Adipose tissue is an endocrine organ and the main function is to store 
triglycerides as an endogenous fuel that are used upon metabolic demand and 
for body insulation. Together with liver and skeletal muscle, adipose tissue is 
responsible for the maintenance of insulin stimulated glucose uptake. There 
are two different types of adipose tissue: white adipose tissue (WAT) and 
brown adipose tissue (20). The knowledge in mechanisms that control 
browning of the white adipose tissue is advancing and it might have potential 
therapeutic applications (21). Largest WAT depots in humans are the 
subcutaneous and the visceral depots. WAT is composed of different cells 
types: adipocytes and connective stroma-vascular fraction which contains pre-
adipocytes, fibroblasts, leukocytes, adipose tissue macrophages, lymphocytes, 
endothelia and mesenchymal stem cells where all have different functions (22). 
Furthermore, WAT is involved in production and secretion of adipokines 
(cytokines) such as leptin, resistin and adiponectin that are involved in 
regulation of metabolic homeostasis and vascular health (23). Normal function 
of adipose tissue is disturbed by increase in body weight (24).  According to 
the World Health Organization (WHO) obesity is causing death of 2.8 million 
people each year in high income countries, which is as a direct result of 
abnormal fat accumulation (25). In October 2017 WHO released new numbers 
concerning overweight, obesity, and the new number calls for rapid measures:  
 Worldwide obesity has nearly tripled since 1975 
 In 2016, more than 1.9 billion adults, 18 years and older, were 
overweight. Of these over 650 million were obese 
 39% of adults aged 18 years and over were overweight in 2016, and 
13% were obese 
 Most of the world's population live in countries where overweight 
and obesity kills more people than underweight 
 41 million children under the age of 5 were overweight or obese in 
2016. 
 Over 340 million children and adolescents aged 5-19 were 
overweight or obese in 2016 
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Women with PCOS are often overweight or obese and adiposity leads to 
metabolic complications such as insulin resistance with compensatory 
hyperinsulinemia and glucose intolerance, which increases risk of developing 
type 2 diabetes (26). There is evidence that several regulatory processes in 
WAT such as lipolysis, adipose tissue morphology and vascularization are 
altered, which associates white adipose tissue changes with PCOS 
pathophysiology (27).The strongest factors explaining insulin resistance in 
women with PCOS are the increased adipocyte size together with decreased 
circulating levels of adiponectin (28). Furthermore, women with PCOS have 
alterations in adipokine levels. Adiponectin is produced only in adipose tissue 
and has insulin-sensitizing, anti-inflammatory and anti-atherosclerotic 
properties (29). Levels of adiponectin are inversely related to body weight, 
insulin resistance and type 2 diabetes (30). Several studies have shown that 
women with PCOS have lower adiponectin levels when compared to controls 
(31, 32). Moreover, it was demonstrated that low adiponectin levels were 
associated with insulin resistance and not with testosterone suggesting that 
hyperinsulinemia is a major factor contributing to aberrant levels of androgens 
from the ovaries (32). Leptin is another adipokine that regulates energy 
homeostasis and controls reproductive functions. High levels of leptin are 
associated to insulin resistance, obesity and metabolic syndrome (33). In 
women with PCOS the results are conflicting. Some studies suggest there is no 
difference in circulating leptin levels (34), while other studies showed 
increased levels of leptin in women with PCOS in comparison to the controls 
(35).  
Overweight and obesity together with lack of exercise and physical inactivity 
have become a problem in developed countries that often lead to development 
of metabolic disorders such as: dyslipidemia, hypertension, inflammation, 
development of cardiovascular diseases and increased production of 
testosterone and estradiol (36, 37). 
1.4.2 Skeletal muscle  
Skeletal muscle is one of the most dynamic tissues in human body that controls 
multiple body functions such as the movement and different metabolic process. 
Human body consists of around 600 muscles, which are controlled by the 
nervous system (38). Skeletal muscle is involved in regulating energy 
metabolism, storage of amino acids and carbohydrates. Furthermore, it 
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accounts for 75% of insulin stimulated glucose uptake from the blood and is a 
key factor in regulating whole-body glucose homeostasis (39). Together with 
brown adipose tissue and liver, skeletal muscle regulates the heat production 
and controls the peripheral glucose uptake (40). Therefore, it is important to 
maintaining optimal skeletal muscle health through life and prevent 
development of metabolic disturbances such as insulin resistance, metabolic 
syndrome, obesity and chronic diseases. 
Insulin resistance is characterized as decreased ability of cells to respond to 
insulin. PCOS is likely to be complicated into other comorbidities such as type 
2 diabetes and cardiovascular diseases because of disturbances in glucose 
uptake in both adipose tissue and skeletal muscle. (41, 42). The mechanisms 
of insulin resistance are partly known and the factors that contribute to the 
development of prediabetes and insulin resistance are attributed to genetics, 
age and life style (43). The prevalence of insulin resistance in women with 
PCOS is between 50-70% (44). Interestingly, insulin resistance in women with 
PCOS is independent of obesity. This indicates that there are other drivers of 
insulin resistance than overweight or obesity. Furthermore, elevated insulin 
levels lead to increase in both the production and secretion of androgens from 
the theca cells in the ovaries. In addition, hyperinsulinemia lead to reduction 
of hepatic biosynthesis of sex hormone-binding globulin which subsequently 
increase levels of circulating free testosterone (15).  
Previous studies in skeletal muscle in women with PCOS showed that insulin 
action is reduced and activity of insulin-signaling pathways along with glucose 
uptake was decreased (10). It is believed that the two central mediators in 
development of insulin resistance in PCOS are hyperandrogenemia together 
with hyperinsulinemia (45). The molecular mechanism of insulin resistance 
and the theory that insulin derives hyperandrogenemia in women with PCOS 
are not well investigated and a variety of different factors, genes and pathways 
have been suggested to play an important role (46). Transcriptional alterations 
in insulin signaling pathways phosphatidylinositide 3-kinases (PI3K) that 
regulates insulin stimulated glucose uptake have been demonstrated (47). It 
was shown that women with PCOS have altered activity of two upstream 
mediators in PI3K signaling pathway: IRS-1 and AKT, which could explain 
low insulin sensitivity (47). Data suggested that increased phosphorylation of 
IRS-1 might be connected to hyperandrogenemia and hyperinsulinemia and 
contribute to development of insulin resistance (48). Another pathway that has 
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altered activity in women with PCOS is mitogen-activated protein kinase 
pathway (MAPK) and those disturbances might contribute to insulin resistance 
development (49). In addition, insulin resistance in skeletal muscle in women 
with PCOS has been associated with reduction in mRNA expression in genes 
involved in mitochondrial oxidative metabolism, disturbances in fatty acid 
metabolism and calcium homeostasis (50). It was suggested that insulin 
resistance in women with PCOS is due to the decreased mitochondrial 
respiration (51), however this finding is not supported by other studies, which 
showed that mitochondrial ATP synthesis was not altered in women with 
PCOS (52). Furthermore, it was proposed that myostatin, a common regulator 
of metabolism, is involved in regulation of metabolism of androgens in skeletal 
muscle cells but this finding have not been confirmed (53). It was shown that 
testosterone affects expression of aromatase and androgen receptor without 
affecting insulin sensitivity in women with PCOS (54). The effect of androgens 
on insulin sensitivity in skeletal muscle in humans is unknown and this require 
further research.  
1.5 EPIGENETICS 
In 1956, British developmental biologist Conrad Waddington published a 
paper in the Journal of Evolution where he laid down the principles of today´s 
filed of Epigenetic. He defined epigenetics as ‘‘the branch of biology which 
studies the causal interactions between genes and their products which bring 
the phenotype into being”. Waddington created the model of “Epigenetic 
landscape” (Figure 2) which is a process of cellular differentiation where a 
marble rolls from the top of the hill (which represents the pluripotent state of 
the cell), and during the movement the cell has a potential of differentiating 
into any cell type in the body.  
 
 
 
 
Figure 2. Waddington´s Epigenetic Landscape. Image under public domain.  
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Since then, a numerous of scientific meeting and more than 22 000 published 
papers have studied the epigenome. The modern definition of Epigenetics 
where the concept of inheritance play a big part have been introduced and is 
well accepted by others.  
 “The study of changes in gene function that are mitotically and/or meiotically 
heritable and that do not entail a change in DNA sequence” (55). 
Epigenetic marks can be influenced by the information coming from the 
environment supporting the theory that epigenetic changes can be rapidly 
altered and therefore are involved in controlling the gene expression (56). 
There are different epigenetic mechanisms that are involved in controlling the 
gene expression:  
 DNA methylation  
 Post- translational histone modification  
and  
 Non-coding RNA (ncRNA) 
1.5.1 DNA Methylation 
DNA methylation is the most studied epigenetic mechanism that regulates 
gene transcription and expression. It involves transfer of methyl group from S-
adenosylmethionine to the top of the fifth carbon on the cytosine base (57). 
Addition of methyl group on the top of genomic information controls gene 
transcription and expression without changing underlying DNA sequence. 
Methylation marks are laid down by de novo DNA methyltransferases 
DNMT3A, DNMT3B and DNMT3L (58). After cell division hemi-methylated 
DNA is maintained by DNMT1 methyltransferase enzyme (59). DNA 
methylation can occur in regulatory region of the gene (promoter) but it is more 
traditional to find methyl marks on gene body, intergenic regions and repetitive 
elements. The function of methylation in intergenic regions and repetitive 
elements is to stabilize chromatin, maintain genomic integrity and provide 
genomic stability. Cytosine bases that are followed by guanidine (CpG) are 
usually located in the promoter region and in general, it is believed that these 
CpG regions are protected from methylation. Most cells have a stabile DNA 
methylation pattern where between 70‒80% of CpG sites are methylated (60). 
The field of epigenetics is progressing; however, it is still largely unknown 
how many CpGs are involved in genomic regulation. It has been reported that 
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around 22% of autosomal CpGs within a normal developmental context are 
used and many of those were distal to transcription start sites (61).  
1.5.2 Histone Modification 
Histone modification is another type of epigenetic mechanism that is involved 
in regulation o gene expression. In eukaryotic cells, DNA is wrapped around 
histone octamers (H2A, H2B, H3 and H4) and it forms DNA-histone protein 
complex called nucleosome. In this way, two meter of DNA is tightly packed 
into a chromatin structure. A posttranslational modification of histone N-
terminals is a subject to several modifications including methylation, 
acetylation, phosphorylation, ubiquitination and sumoylation (62). Most 
studies on histone modification are performed on histone acetylation and 
methylation. Histone methylation is associated with both gene activity and 
gene silencing and it comes in different states (mono, di and tri methylation). 
Histone acetylation is a chromatin modification that is associated with gene 
activity only (63).  
1.5.3 Non- coding RNAs 
Non-coding RNAs (ncRNA) have important function in epigenetic regulation 
of the gene transcription at the post-transcriptional level. There are several 
different types of ncRNA that are involved in the epigenetic control: small non-
coding RNAs such as micro RNA, siRNAs, snoRNAs, piRNAs and long non-
coding RNAs such as XIST and HOTAIR (64). The role of non-coding RNAs 
in PCOS is limiting. Some studies aimed to identify differentially expressed 
micro RNAs and associate them to impaired glucose metabolism, reduced 
insulin sensitivity and disturbances in steroidogenesis (65, 66). However, these 
finding are not well established and, further research has to be carried through 
to demonstrate the involvement of non-coding RNAs in pathophysiology of 
PCOS.  
1.5.4 Epigenetics in PCOS 
PCOS is a heritable disorder, however, no genes responsible for the 
development have been found. Therefore, it has been proposed that the origin 
and the development of PCOS could be a result between an interaction in 
genetic and epigenetic alterations (67). There are limited numbers of human 
studies that have profiled epigenome in women with PCOS although, with the 
new emerging techniques being developed, new data is being generated 
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constantly. The first implications of epigenetic involvement in development of 
PCOS came from studies performed on PCOS rhesus monkey model (68) 
which hypothesized that foetal hyperandrogenemia might be responsible for 
altering the epigenome and lead to development of PCOS in adolescence (69, 
70).  
This theory suggest that PCOS might originate in fetal life, where elevated 
maternal androgens might have been implicated to play a role in altering the 
faith of foliculogenesis and this would lead to development of PCOS however, 
the mechanisms are largely unknown (71, 72). It is known that abnormal 
exposure to androgens and glucocorticoids during critical intrauterine periods 
during pregnancy leads to development of different PCOS phenotypes (73). 
Another theory suggested that PCOS might be a disorder related to 
environmental conditions such as diet (74). Caloric restriction during 
pregnancy leads to hypoxia consequently leading to restricted intrauterine 
growth and therefore smaller birth weight (75). Therefore, PCOS would 
manifest itself later in adolescent life as a way to compensate for insufficient 
intrauterine growth (75). The genome-wide screen epigenetic studies 
suggested that methylation disturbances in skeletal muscle, adipose tissue (76) 
and ovaries (77) are due to the diet, obesity, sedentary life and environmental 
factors (78). The enormous efforts have been put into generating extensive 
amount of methylation microarray data. However, the results from different 
epigenetic studies in tissues such as adipose tissue (76, 79) and blood (80-82), 
are conflicting and further research is needed to elucidate if methylation 
changes are leading to transcriptional changes that could explain pathogenesis 
of PCOS..  
1.6 TREATMENT FOR PCOS 
There is no cure for PCOS but there are different strategies to treat the 
symptoms. The first line treatment for women with PCOS, independent of 
obesity, is lifestyle modifications including weight reduction and physical 
exercise to improve reproductive and metabolic function (83). Sedentary 
lifestyle, nutrient overload and poor physical activity lead to excessive fat 
accumulation in some PCOS phenotypes. Overweight or obesity can be 
prevented with regular physical activity/exercise (60 minutes a day for children 
and 150 minutes spread through the week for adults, WHO, 2017). Women 
with PCOS have often decreased insulin sensitivity and lifestyle changes are 
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the first line of treatment (84). Furthermore, physical activity and exercise 
improve metabolic health and beneficial effects of exercise have been shown 
on the mental health of women with PCOS (85). Pharmacological 
administration is a conventional management to control the symptoms. 
However, it has many side effects and the goal is not to use pharma as a lifelong 
treatment. Oral contraceptives are effective but they cannot be used in women 
that are trying to conceive. Anti-androgen treatment improves clinical 
symptoms of hirsutism, acne and restores menstrual cyclicity, however, it 
aggravates metabolic profile (86). In women with PCOS metformin is used to 
inhibit ovarian androgen production and improve ovulation (87). Furthermore 
metformin improves whole-body glucose uptake by decreasing hepatic glucose 
production and lowering free fatty acid in liver, skeletal muscle and adipose 
tissue in women with PCOS (88). The exact mechanism of metformin is 
unknown but it enhance glucose uptake in the skeletal muscle, liver and 
adipose tissue (89). In addition, metformin is used when patients do not 
respond to lifestyle modifications and when they do not follow exercise 
regimen (90). Since pharmacological treatment has adverse effect, we are 
searching for other alternative methods to improve metabolic profile. 
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1.7 ELECTROACUPUNCTURE 
Acupuncture is as ancient Chinese practice that is defined as insertion of 
needles into the body at specific points (acupoints). In the western world 
patients usually seek for the treatment of acupuncture when pharmacological 
treatment is unsuccessful. Since pharmacological managements are often 
accompanied by negative side effects, acupuncture has a status of being safe 
and efficient and therefore widely used (91). Acupuncture needles can be 
stimulated either manually by rotation or with low-frequency electrical current 
(1-15Hz), so called electroacupuncture. Low-frequency electroacupuncture 
results in muscle contractions and theoretically, it resembles the effect of 
exercise (92). The mechanisms of acupuncture are not completely known but 
hypothetical models have been proposed. Both manual and low-frequency 
electroacupuncture stimulation activates special type of mechanoreceptors in 
skeletal muscle, so called ergoreceptors, which activates sensory nerve fibers; 
myelinated Aα, β, δ, and unmyelinated C-fibers (93). When needles are 
stimulated, it evokes an activation of sensory nerve afferents. The stimulation 
cause a direct release of a number of neurotransmittors including calcitonin 
gene related peptide, vasointestine peptide, and nerve growth factor to mention 
a few, from the peripheral nerve endings, resulting in a direct, local effect in 
the tissue including increased microcirculation as well as glucose transporter 4 
(GLUT4) translocation to the cell membrane and increased glucose uptake 
(94). In the spinal cord the stimulation modulates spinal reflexes, including 
sympathetic output to organs located in the same somatic innervation area. All 
spinal reflexes are under control of the central nervous system (95). Activation 
of sensory nerve afferent are transmitted to thalamus, hypothalamus and higher 
control centers including limbic structures (96-98). In the hypothalamus is β-
endorphin secreted which has a high affinity for μ-receptor and has been 
demonstrated to regulate general sympathetic activity by decreasing blood 
pressure (99-101). That β-endorphin is involved in the regulation of blood 
pressure is evidenced by the fact that administration of µ-receptor blocker 
diminish the effect of low-frequency electrical stimulation on blood pressure 
(102). Further, β-endorphin is also thought to regulate the gonadotrophin 
releasing hormone secretion pattern which consequently affect he secretion of 
luteinizing hormone and follicle stimulation hormone, and might therefore, 
hypothetically has a regulatory effect on the testosterone production in the 
theca cells (103) (Figure 3).  
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Figure 3. A hypothetical model of the low-frequency electroacupuncture (EA). Needles are 
inserted in abdominal and quadriceps muscle and in muscle below the knee. Muscle contractions 
induces by electrical stimulation activates ergoreceptors that in turn activates afferent Aδ and C 
nerve fibers. Thereafter, the signal of EA is transmitted to the spinal cord where sympathetic 
reflexes can modulates organs that are in the same innervation area. From the spinal cord the 
signal of electroacupuncture can modulated the central nervous system and affect the endocrine 
system (GnRH: Gonadotropin releasing hormone; LH: Luteinizing hormone; FSH: Follicle-
stimulating hormone; CRH: Corticotrophin releasing hormone; DHEA: 
Dehydroepiandrosterone; DHEAS: Dehydroepiandrosterone Sulfate).  
Illustration by Igor Cervenka 
 
In a dihydrotestosterone-induced rat PCOS model, exhibiting irregular cycles, 
obesity and insulin resistance, both a single bout of low-frequency 
electroacupuncture and repeated electroacupuncture treatment have been 
shown to increase whole-body glucose uptake and restore dysfunctional 
adipose tissue gene expression (104-106). Whether acupuncture improves 
whole- body glucose regulation and cellular function in skeletal muscle and 
adipose tissue of women with PCOS is unknown. Repeated combined manual 
and low-frequency electroacupuncture has been shown to ameliorate excessive 
sex steroid secretion and to improve ovulatory function (107, 108), an effect 
that has been attributed to a decrease in a high sympathetic nerve activity (109, 
110). However, in a recent large randomized controlled trial investigating 
whether low-frequency electroacupuncture is as good as pharmacological 
treatment with clomiphene citrate, or if it potentiates the effect of 
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pharmacological treatment for live birth rate in infertile women with PCOS, it 
was shown that clomiphene citrate was superior to acupuncture on live birth 
rate (111).  
Human obesity is characterized by increased sympathetic nervous resulting 
that leads to hypertension, increased lipolysis, and elevated free fatty acids in 
circulation, which is related with insulin resistance, overweight and obesity 
(112, 113). It is largely unknown if increased sympathetic activity is a cause 
or a consequence of obesity and insulin resistance results (114). There are 
clinical evidence of acupuncture regulating sympathetic nervous system (109). 
However, the clinical effectiveness together with mechanistic evidence of 
acupuncture leading to improvement of insulin sensitivity and other metabolic 
abnormalities in women with PCOS are sparse. Therefore, in paper III and IV 
in this thesis, we have studied the effect and possible mechanisms of action of 
a single bout of low-frequency electroacupuncture on whole-body glucose 
uptake.  
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2 AIM 
The overall aim of this thesis is to study if women with PCOS have altered 
methylation and expression patterns in adipose tissue and skeletal muscle. 
Subsequently we aim to examine if a single bout of low-frequency 
electroacupuncture has the potential to improve insulin sensitivity in 
overweight and obese women with PCOS. Moreover, whether epigenetic 
alterations in subcutaneous adipose tissue in women with PCOS can be 
remodeled by the stimulation. In addition, we have studied the mechanisms by 
which electroacupuncture mediates its effect.  
SPECIFIC AIMS 
Study I  To analyze genome-wide DNA methylation and gene 
expression levels in adipose tissue from women with PCOS and controls. In 
addition, to replicate these findings we used unrelated subjects and a new case- 
control cohort. 
Study II  To analyze genome-wide DNA methylation and gene 
expression levels in skeletal muscle tissue from women with PCOS and 
controls. In validation in vitro experiments in human female myotubes we 
aimed to study the effect of insulin and testosterone on expression of selected 
genes as well as glycogen synthesis. 
Study III  To study the effect of a single bout of low-frequency 
electroacupuncture on whole-body glucose uptake in overweight and obese 
women with and without PCOS. Furthermore, we aimed to test if increased 
glucose uptake by electroacupuncture is mediated via activation of the 
autonomic nervous system and the opioid system in rodents. 
Study IV  To test if a single bout of low-frequency electroacupuncture 
remodels genome-wide DNA methylation and gene expression pattern in 
subcutaneous adipose tissue in women with PCOS. In addition, we aimed to 
study if changes in gene expression are mediated via activation of the 
sympathetic nervous system.  
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3 PATIENTS  AND METHODS 
3.1 ETHICS  
The Regional Ethical Review Board of the University of Gothenburg approved 
all human studies (paper I-IV) in this thesis. All studies were conducted at the 
Sahlgrenska Academy, University of Gothenburg and at the Sahlgrenska 
University Hospital, Gothenburg, Sweden, in accordance with the Declaration 
of Helsinki. All participants gave oral and written consent before inclusion. 
The animal experiment (paper IV) was approved by the Animal Ethics 
Committee of the University of Gothenburg, Sweden, and followed the 
principles of the Guide for the Care and Use of Laboratory Animals.  
3.2 HUMAN STUDY 
3.2.1  Subjects  
We used two different cohorts of women. Subjects in cohort 1 are presented in 
paper I and subjects from cohort 2 are presented in paper II-IV. All women 
were recruited by advertisements in local newspapers and in frequently visited 
places in the community. A thorough anamnesis was taken before the 
participants were included in the study.  The eligibility criteria for women with 
PCOS were at least two of the following three signs: 
1. Polycystic ovarian morphology (PCOM) 
2. Clinical and/or biochemical signs of hyperandrogenism  
3. Oligo/amenorrhea. 
 
The PCOS inclusion criteria for cohort 1 were:  
a) Ultrasound-verified polycystic ovaries with 12 or more 2–9 mm 
follicles and/or ovarian volume ≥10 ml in one or both ovaries.  
b) A self-reported Ferriman-Gallwey (FG) score ≥ 8 was defined as 
hirsutism with or without acne as defined by a positive response to 
the question Do you have acne Yes/No?  
and/or  
c) Oligomenorrhea was defined as an intermenstrual interval >45 days 
and < 8 menstrual bleedings in the past year. Amenorrhea was 
defined as < 3 menstruations per year.  
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The inclusion criteria for subjects in cohort 2 were the same but PCO 
morphology was not mandatory i.e. a) and/or b) and/or c). 
The exclusion criteria for controls were:  
a) Evidence of PCO morphology 
b) Clinical signs of excessive acne or hirsutism 
c) Menstrual irregularities (cycles >35 days) 
The exclusion criteria for all women were: 
a) Endocrine disorders such as hyperprolactinemia, non-classic 
congenital adrenal hyperplasia, androgen-secreting tumors, 
Cushing´s syndrome 
b) Autoimmune disorder 
c) Cancer 
d) Type I or type II diabetes 
e) Cardiovascular disease 
f) Pharmacological treatment within 12 weeks before inclusion 
g) Breastfeeding for 6 months before inclusion 
In paper I we included 30 controls and 64 women with PCOS over a wide 
range of BMI. Out of 64 women with PCOS, 49 women met all three criteria 
for the PCOS diagnosis: PCO morphology; clinical signs of hyperandrogenism 
and ooligo/ amenorrhea and 15 women had hyperandrogemia and PCO 
morphology.  
 
In paper II−IV was 21 women with PCOS and 21 controls included. 
Seventeen out of 21 women with PCOS met all three PCOS criteria. Cases and 
controls were matched for, age, weight and BMI. 
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3.2.2  Assessment of Insulin Resistance 
There are different methods to test for disturbances in insulin sensitivity. 
Insulin resistance is simply diagnosed by oral glucose tolerance test (OGTT), 
which is a non-invasive method. Insulin sensitivity is also assessed by 
calculations of different sensitivity indexes such as: homeostasis model 
assessment (HOMA) and quantitative insulin sensitivity check index. These 
methods are regularly used in a routine clinical practice however; they are not 
as consistent and reliable as direct measurement of insulin resistance by 
euglycemic- hyperinsulinemic clamp technique, which is considered the gold 
standard method (115).  
The euglycemic- hyperinsulinemic clamp technique has been described in 
detail by others (116). In brief, after an overnight fast, insulin is infused at 
constant rate until a new hyperinsulinemic steady-state is reached. In theory 
this leads to a complete suppression of hepatic glucose production. Insulin is 
infused in a constant rate while exogenous glucose is infused at variable levels 
in order to avoid hypoglycemia and maintain euglycemia. The clamped levels 
of glucose provide information on how much of glucose is being metabolized 
per kilo of body weight when insulin levels are at the constant rate.  
In paper I during euglycemic- hyperinsulinemic clamp insulin was 
continuously infused at 120 mU/m2/min in paper II insulin was infused at 
40mU/m2/min for 120 min to reach steady state.  
Therefore, insulin resistance is proportional to the amount of glucose cleared 
from the blood and low glucose infusion rate indicates insulin resistant 
patients. In all papers in this thesis, we estimated insulin sensitivity by 
calculating HOMA-IR and HOMA-B indexes and by euglycemic– 
hyperinsulinemic clamp technique.  
3.2.3 Human Samples 
Tissue biopsies were collected from musculus vastus lateralis and abdominal 
subcutaneous adipose. All biopsies were collected under local anesthesia 
(Xylocain, 20mg/ml, AstraZeneca AB, Södertälje, Sweden). Human skeletal 
muscle biopsies were collected by using a Bergström needle, and the 
subcutaneous adipose tissue were collected with needle biopsy. Adipose tissue 
biopsies were immediately rinsed with saline and prepared for further analyses.  
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After overnight fast, blood was collected from all participants and circulating 
hormones, lipid profile and adipokines were analyzed in an accredited 
laboratory. Clinical characteristics of all subjects and study design are 
presented in papers I-IV respectively.  
3.2.4  Laboratory analyses  
In study I Serum SHBG was measured with a chemiluminescent microparticle 
immunoassay (CMIA) (Architect SHBG reagent kit; Abbott Laboratories, 
Diagnostic Division, Chicago, IL). Gas chromatography/mass spectroscopy 
(GC-MS) was used to analyze serum testosterone and serum 17β-estradiol. 
Free testosterone and free estradiol were calculated as described by Vermeulen 
et al. (23) and Van den Beld et al. (24).  
In study II and IV plasma glucose was measured by One Touch Ultra2 
(LifeScan). Insulin was analyzed at an accredited laboratory. Serum insulin 
was measured with immunometric two-step sandwich method (Advia Centraur 
Insulin Ready Pack; Bayer HealthCare) where two antibodies are used: anti- 
insulin (Lite Reagent) and a monoclonal mouse anti-insulin antibody (Solid 
Phase) to initiate a chemiluminescence reaction. Serum C-peptide was 
measured with a human diabetes C-peptide magnetic bead set (Bio-Rad, USA). 
Plasma noradrenaline, dopamine, DOPAC, HVA, serotonin, and 5HIAA were 
measured on a split-fraction HPLC-ED system (117). Serum testosterone and 
estradiol were measured by gas chromatography-tandem mass spectrometry 
(GC-MS/MS) (118). In study IV subcutaneous adipose tissue levels of 
dehydroepiandrosterone (DHEA), androstenedione, testosterone, 
dihydrotestosterone (DHT), estrone (E1), estradiol (E2), and progesterone 
were measured by GC-MS/MS as previously described (119, 120). 
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3.2.5  Adipocyte size 
To determine the adipocyte size we used a relatively quick method based on 
collagenase treatment accompanied by computer image analysis. Fresh adipose 
tissue (approximately 500mg in paper I and 250mg in paper II and IV) was cut 
and treated with collagenase (Typ A; Roche, Mannheim, Germany) in essential 
medium (Invitrogen, Carlsbad, CA) for 50 minutes at 37°C in a shaking water 
bath. Adipocytes were filtered and washed through 250 μm nylon mesh, then 
suspended in fresh medium. A drop of adipocyte cell suspension was placed 
between a siliconized glass slide and a cover slip and transferred to the 
microscope stage (Axioplan 2 imaging, Carl Zeiss, Oberkochen, Germany; ×5 
objective). Mean adipocyte diameter was determined by using computerized 
image analysis as previously described (20). Nine random fields were 
photographed with a CCD camera (Axiocam, Carl Zeiss). Images were 
analyzed with Leica software (QWin V3, Leica Microsystems, Wetzlar, 
Germany).  Mean adipocyte volume was calculated with the Goldrick formula 
(21). Although the method is convenient and provides reliable measurement of 
mean cell size, it has some disadvantages. During preparation of adipocyte 
suspension, collagenase treatment can lead to rapture of large adipocytes 
resulting with lipid droplets, which are then manually removed during 
computerized images analysis. This process is time consuming and it can be 
difficult to distinguish between small adipocytes and lipid droplets. 
Furthermore, this method does not provide information on the size distribution 
of the adipocytes.  
3.2.6 Human Skeletal Muscle Cells Experiments  
One objective of the cell experiment was to investigate if the two key features 
of PCOS, hyperandrogenism and hyperinsulinemia are controlling the gene 
expression. For these experiments, we selected in total 13 genes to study: 
DYRK1A, SYNPO2, KLF10, SCP2, NAMPT, FOXO3, ING2, TTN, PPP2R2D, 
THY1, MAP2K6, YWHAE and COL1A1. Cells from four healthy young donors 
were exposed to testosterone and/or insulin for three days and gene expression 
levels were compared to women with PCOS. We used following substances to 
stimulate cells: Testosterone, CDX (Bicalutamide, androgen antagonist) and 
insulin.  
The second objective of these experiments was to investigate the effect of 
androgens on glycogen accumulation. Human female myotubes were 
stimulated with insulin, testosterone, and CDX and the effect of the substances 
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on the glycogen synthesis was measured. The conditions used in the human 
cells experiment and the process of myotube stimulation are described under 
Material and Methods in paper II.  
 
3.3  ANIMAL STUDY PROCEDURE 
The aim of the animal experiment in paper III was to study the mechanisms 
by which electroacupuncture mediates its effect on whole-body glucose 
uptake. All experiments were performed in the estrous phase and rats were 
randomly divided into treatment or no-treatment group. We conducted an 
experiment where we performed euglycemic-hyperinsulinemic clamp on rats 
and measured if one single bout of electroacupuncture affects whole-body 
glucose uptake in controls and DHT-induced PCOS rats. To investigate if the 
effect of acupuncture is mediated via autonomic nervous system and/or via the 
opioid system, we administrated different pharmacological agents. The dosage 
of the blockers used in this study were selected from the previous defined and 
established experiments (121, 122). Firstly, we identified responders to 
electroacupuncture as those that have increased in glucose infusion rate by 
15% at 25 minutes of stimulation. Bolus dose of blocking agents of naltrexone 
(10mg/kg), Atropin (1mg/kg), Butaclamol (2mg/kg), Phentolamine (5mg/kg), 
Propranolol (1mg/kg) and saline were administrated at 30 minutes. After the 
bolus dose, atropine (0.5mg/kg), butaclamol (1mg/kg), phentolamine 
(7mg/kg/h), propranolol (0.5mg/kg/h) were continuously infused. Study 
design can be find in paper III Figure 1B.  At steady-state of euglycemic-
hyperinsulinemic clamp, two acupuncture needles were placed in the rectus 
abdominis muscle- which corresponds to the acupuncture points ST27, ST28, 
and ST29- and two were placed in the triceps surae muscle bilaterally– which 
corresponds to SP6 and SP9. The needles were attached to an electrical 
stimulator (CEFAR ACU II; Cefar-Compex Scandinavia, Sweden) and 
stimulated with low-frequency (2 Hz) at an intensity high enough to evoke 
muscle twitches, which varied from 0.8 mA to 2.2 mA due to receptor 
adaptation. The euglycemic-hyperinsulinemic clamp was performed under 
general anesthesia. Insulin was continuously infused at 8 mU/kg/min, and 
glucose was infused to maintain euglycemia of 6 mM.  
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3.4  SUMMARY OF THE METHODS (PAPER I–IV) 
Table 2. Summary of methods used in the thesis.   
  
 
 
Methods Paper I Paper 
II 
Paper 
III 
Paper IV 
Euglycemic–
hyperinsulinemic clamp 
        
Adipocyte Size       
LC/MS and GC/MS       
HPLC-ED      
TaqMan Micro Fluid Cards       
RT-qPCR /SYBR        
Immunoblot Analysis      
Illumian HumanHT-12 v4 
Expression BeadChip  
 
       
Illumina Infinium Human 
Methylation450k BeadChips 
       
Ingenuity Pathway Analysis        
Gene Set Enrichment 
Analysis 
     
ELISA         
Human Skeletal Muscle 
Cells 
     
Electroacupuncture       
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3.5 GENOME-WIDE EXPRESSION ARRAY AND REAL TIME QPCR  
In this thesis, we studied genome-wide gene expression in adipose tissue 
(paper I and IV) and in skeletal muscle (paper II) by using Illumina 
HumanHT-12 v4 Expression Bead Chip array. This array provides genome-
wide transcriptional coverage of 47 000 probes that represent well-
characterized genes, gene candidates and unknown splice variants.  
In all papers in this thesis RNA was extracted with commercial column based 
RNA extraction kit (Qiagen) using the Trizol reagent. The RNA concentrations 
and purity were assessed with a NanoDrop spectrophotometer 1000 (Thermo 
Fisher Scientific) and RNA integrity was determined with automated 
electrophoresis method (Experion, Bio-Rad). 
In paper I, II and IV, cRNA synthesis for genome- wide expressions studies 
were carried out at Genomic Core facility at University of Gothenburg, by 
using Illumina TotalPrep RNA Amplification Kit (Life Technologies & 
Invitrogen).   
In validation experiment in paper I, Taq-Man assay micro fluid cards (Life 
technologies) were used to measure mRNA abundance of selected genes. We 
selected to use Taq-Man probes to measure mRNA abundance of selected 
genes due to the high specificity and efficiency.  
In paper II and IV, we synthesized a stabile cDNA by using High- capacity 
cDNA Kit (Thermo Fisher Scientific). Abundance of the mRNA transcripts in 
human cell experiment (paper II) and animal experiment (paper IV) were 
measured by SYBR Green real-time PCR reactions (Applied Biosystem).  
In all papers, we used reference housekeeping genes that are stable in the 
tissues and not affected by the treatment.  We used the algorithms of the 
NormFinder (123) to find the best combination of the housekeeping genes for 
the normalization.  
3.6 GLOBAL METHYLATION ARRAY  
The analysis of DNA methylation levels in adipose tissue (paper I and IV) 
and skeletal muscle (paper II) are separated into two major steps: a) bisulfide 
conversion and, b) genome-wide methylation DNA analysis.  
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Prior to the DNA methylation screening, as recommended, DNA was 
converted from unmethylated cytosines to uracil. We used ʹof-the-shelf΄ 
bisulfite conversion kit (Zymo Research). The bisulfite conversion involves 
four major chemical steps: denaturation where DNA strands are separated; 
Sulfonation and a treatment with sodium bisulfite (NaHSO3) that results with 
addition of SO3- and creation of cytosinsulphonate. In a reaction of hydrolytic 
deamination, loss of water and ammonia leads to formation of 
uracilsulphonate. In a last step in a reaction of desulphonation uracil is formed. 
The methylated cytosines remain unchanged during the bisulfite conversion.  
During the downstream reaction of PCR, uracil is replaced by thymine, which 
during the sequencing step is read out as unmethylated cytosine. The bisulfite 
conversion is a critical step and we have performed a random quality check to 
confirm the successful bisulfite conversion Figure 4.   
 
Figure 4.  Chemical reaction of bisulfite conversion of cytosine to uracil.  
                   Illustration: Igor Cervenka 
 
To analyze multiple methylation sites we used a high-throughput methylation 
array from Illumina Infinium® HumanMethylation450k BeadChip array. The 
array covers 485577 cytosine methylation sites which cover 99% of the 
reference sequence (RefSeq) genes and 96% of CpG islands. The array also 
gives information on location of the non- CpG sites and SNPs. 
HumanMethylation450k BeadChip is a two color assay that is based on 
Infinium I assay and Infinium II study design. Infinium I assay depends upon 
the base preceding the CpG locus being queried. Infinium II design depends 
on a single base extension at the 3' end of the probe sequence. Both designs 
will result in either red or green signal, depending on if CpG sites is methylated 
(red) or unmethylated (green). Methylation levels in BeadChip array are 
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measured for each CpG locus by calculation of a beta value (β). To estimate 
the levels of methylation and the beta value, the ration between intensity of 
methylated and unmethylated allele is calculated using β = Im/(Iu+Im+α), 
where Im represents methylated probe and Iu unmethylated probe, α is a 
constant. (124). Beta values range is between 0-1 and which represents the 
level of methylation between 0-100% within the specific cell pool.  
3.7 WESTERN BLOT ANALYSIS  
Protein concentrations were measured by Direct Detect™ spectrometer 
(Millipore, Billerica, USA). In paper I we used monoclonal antibodies that 
were specific against CYP1B1 (AV51761, Sigma-Aldrich, Stockholm 
Sweden) and PPARG (ab191407, Abcam, Cambride, UK). The protein 
analysis is challenging, comprehensive and time-consuming technique and we 
experienced different problems. In paper I, we optimized the signal strength 
of the PPARγ antibody in adipose tissue by increasing protein concentration 
and optimizing the concentration of our primary and secondary antibodies.   
In paper III protein concentration was quantified by the Bradford assay. The 
protein levels of mNGF and proNGF were measured using MAB5260Z clone 
27/21 and EP1318Y antibodies (Merck Millipore, Billerica, MA, USA) in a 
homemade sandwich ELISA.  
3.8 PATHWAY ANALYSIS  
3.8.1 Ingenuity Pathway Analysis 
Ingenuity pathway Analysis (IPA) is an online research tool based on 
experimental knowledge libraries that was used for functional characterization 
of DNA methylation and genome-wide expression microarray data. We used 
IPAs canonical core analysis to investigate functional enrichment in expression 
and methylation differences between cases and controls (paper I and II) linked 
with metabolic disturbances in women with PCOS. In paper IV we used IPA 
to characterize pathways before vs after single bout of electroacupuncture that 
might be affected by treatment.   
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3.8.2  Gene Set Enrichment Analysis (GSEA) 
GSEA is also known as functional enrichment analysis that we used in paper 
II on genome-wide expression array. Here we aimed to provide evidence that 
there is an association between a certain biological pathways (differentially 
expressed genes within the pathway) and the disease that we study (PCOS). 
Data analysis is based on their gene set ranking rather than on the individual 
genes that were ranked according to differences of expression between PCOS 
and controls.  
3.9  STATISTICAL ANALYSIS  
Statistical details for each clinical and experimental study are presented in 
respective manuscript. Gene expression data and DNA methylation levels in 
all experiments are expressed as Mean ± SD. In study I, II and IV we applied 
false discovery rate corrections (FDR) to account for different probe types on 
the array type I and type II when testing for multiple comparisons. We used t-
test to identify differences in DNA methylation data between women with 
PCOS and controls (Paper I, II and IV). Furthermore, we applied the chi–
square test to calculate whether the changed methylated sites were more than 
the expected number by chance. Spearman correlation coefficient were 
calculated to determine association between gene expression and DNA 
methylation.  
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4 RESULTS AND DISCUSSION  
DNA methylation and gene expression differences in subcutaneous adipose 
tissue and skeletal muscle  
There is a growing interest in understanding the involvement of epigenetic 
mechanisms in the development of PCOS (125). Data produced with new 
available technologies are still limited and it is difficult to connect methylation 
differences to the pathophysiology of PCOS. Further, no mechanistic studies 
have been done to verify the involvement of e.g. methylation mechanism in 
PCOS. From epigenetic studies in e.g. cancer (126), it became obvious that 
genetic and epigenetic mechanism cooperate together to control the genomic 
transcriptions and development of a disease (127). Therefore, it should be held 
in mind that all methylation difference identified in our studies are connected 
to underlying genetic disturbances in women with PCOS. 
Firstly, we demonstrate that women with PCOS are more insulin resistant and 
have low glucose disposal rate independent of BMI. Insulin sensitivity was 
measured by the gold standard method; euglycemic- hyperinsulinemic clamp 
and by calculating HOMA-B and HOMA-IR indexes. We have confirmed 
previous findings that women with PCOS have; enlarged adipocytes and 
higher circulating HbA1c,  triglycerides, LH/FSH ratio, C-peptide index, and 
testosterone in comparison to age and BMI the controls (18, 128-130). 
Increased levels of testosterone could explain increased BMI (131) because 
overweight and obesity are associated to increased levels of androgens and this 
in addition explains insulin resistance in some PCOS phenotypes (132). 
However, in our studies we have not seen association between increased 
testosterone and insulin resistance (19).  
In this work we established that absolute differences in gene expression in 
skeletal muscle are larger (expression range 21–186%) than gene expression 
in subcutaneous tissue (expression range 28–58%) suggesting that skeletal 
muscle is more sensitive to transcriptional changes than adipose tissue. 
Whether DNA methylation changes in skeletal muscle are involved in inducing 
the large transcriptomic changes we observed is not clear. Over 17 000 CpG 
sites were differently methylated but only two genes differed after FDR 
corrections; (annotated to C3orf58 and cg10074626 (intergenic)). As ~30% of 
the significantly methylated CpG sites were in or near the gene correlated with 
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differently expressed genes in women with PCOS, this supports a functional 
role of DNA methylation in the skeletal muscle phenotype in these individuals. 
Although smaller expression differences, we identified more alterations in both 
genome-wide methylation and mRNA expression in adipose tissue than in 
skeletal muscle. Our requirements after corrections for the multiple testing in 
adipose tissue were set to FDR of 15% (or q< 0.15). When those requirements 
were fulfilled, we identified 440 differentially methylated sites with the 
absolute difference between 0.24–6.28% in adipose tissue. Out of those, we 
found 33 differentially methylated sites to have corresponding transcriptional 
changes in 30 genes. In skeletal muscle we found 24 differentially methylated 
genes (p< 0.05 and q= 0.84) to correspond to 21 differentially expressed genes 
with the absolute changes in methylation were between 0.48–4.35%. This 
shows that there might be methylation differences that are involved in 
regulation of phenotypic presentation of the PCOS syndrome in subcutaneous 
adipose tissue. Previous methylation studies have demonstrated that small 
alterations in DNA methylation within the regulatory regions of the genes 
might result with large phenotypical alterations (133). Even though we 
identified small changes in DNA methylation in adipose tissue, they still might 
have biological significance and contribute to the development of PCOS.   
We identified 1720 differentially expressed genes with FDR below 5% in 
adipose tissue and differences were up to 58% between women with PCOS and 
controls. We focused on finding the genes with alteration in mRNA that might 
be the main contributors to development of metabolic alterations in PCOS. For 
the first time we identified transcriptional alterations in adipose tissue in 
women with PCOS in: GPT, RTN4, BCKDHA and SVEP1 which, were 
associated with increased adipocytes size, testosterone and glucose disposal 
rate in women with PCOS. Genome–Wide Association Studies (GWAS) 
identified BCKDHA as a candidate gene for obesity (134). It belongs to a 
family of branched-chain amino acids genes (BCAAs) and it might be involved 
in development of insulin resistance (135). Furthermore, we also found a 
positive correlation between methylation and gene expression in GPT and 
negative correlation in BCKDHA, suggesting that epigenetic alteration might 
contribute to development of insulin resistance by altering the mRNA levels 
of these genes in adipose tissue.  
Furthermore, we found that methylation levels of Ras-related protein (RAB5B) 
were increased in average by 1.2% that were associated to decreased mRNA 
 29 
 
expression by 5% in adipose tissue. This goes in line with findings that increase 
in methylation lead to silencing of gene expression (136). GWAS identified 
RAB5B as a PCOS candidate gene (137). Hyperandrogenism is a major driver 
of PCOS (138). It has been proposed that RAB5B is involved in the signaling 
network regulating androgen synthesis (139). Here we could speculate that 
mRNA expression alterations may play an important role in contributing to 
development of hyperandrogenemia. However, additional studies are needed 
to firstly determine the exact function of RAB5B and, if so, how methylation 
differences in RAB5B play a role on transcriptional level that subsequently can 
be connected to alterations in androgen levels and development of insulin 
resistance in PCOS. 
Also in skeletal muscle we wanted to associate differences in mRNA 
expression to the genes that might be involved in development of metabolic 
phenotype in women with PCOS. Skeletal muscle is a major organ involved in 
regulating whole-body glucose uptake and we intended to interrogate glucose 
metabolism in skeletal muscle. Exact molecular mechanisms explaining 
insulin resistance in skeletal muscle in women with PCOS has not been 
identified. Firstly, we performed correlations between genes with largest 
expression differences and clinical characteristics of PCOS. In skeletal muscle, 
we identified several significant correlations between gene expression in 
KLF10, ING2, GGTL3, MAPKAP1, COL1A1, PPP2R2D and NAMPT, and 
circulating testosterone, insulin levels, C-peptide, HOMA-IR and HOMA-B 
and adipocyte size. ING2 is a chromatin remodeling protein involved in muscle 
differentiation (140). The family of GGT enzymes is important for metabolism 
of glutathione, however the function of GGTL3 has to be elucidated (141). The 
role of MAPKAP1 is not defined in skeletal muscle. Previous studies have 
showed that mRNA levels of COL1A1 are affected by over-nutrition, which 
induces changes on muscle extracellular matrix and leads to obesity and 
metabolic dysfunctions (142). PPP2R2D is involved in regulation of a number 
of metabolic processes such as lipid metabolism and lipid biosynthesis (143). 
NAMPT positively regulates glucose homeostasis and this gene plays a role in 
several biological processes (144). These are the genes with the largest mRNA 
expression differences in skeletal muscle between cases and controls and these 
transcriptional alterations might be associated with low glucose uptake and 
insulin resistance. Therefore, we propose that these genes should be elucidated 
in future studies. 
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Further, we overlapped differentially expressed genes in adipose tissue and 
skeletal muscle from the gene expression array in order to find targets to study. 
We overlapped the 85 differentially expressed genes in skeletal muscle with 
1720 unique genes in adipose tissue and found sixteen common genes, whereof 
nine genes changed in the same direction e.g. KLF10 that is involved in glucose 
metabolism.   
We generated large amount of data from both DNA methylation and gene 
expression arrays in paper I and paper II and it is not the scope of this thesis to 
elucidate them all. Whether it is hyperandrogenemia and/or hyperinsulinemia 
that drives the PCOS phenotype is not completely understood (145). There are 
clear indications that androgens contribute to development of metabolic 
alterations in PCOS (146). Likewise, studies propose that hyperinsulinemia is 
the main player contributing to the PCOS phenotype by stimulating the ovarian 
theca cells to produce testosterone and to be involved in development of 
metabolic and reproductive alterations in women with PCOS (147). Support 
for the latter hypothesis comes from studies demonstrating that low insulin 
lowers aberrant levels of androgens (148). However, it is still unknown if it is 
the hyperandrogenemia and/or hyperinsulinemia that drives the development 
of metabolic alterations in PCOS. Therefore, we aimed to explore this 
‘phenomenon’ by investigating effects of insulin and testosterone on glycogen 
synthesis and the expression of selected genes in myotubes of human female 
donors.  
Firstly, as expected, in study IV we confirm that insulin is a strong regulator 
in the conversion of glucose to glycogen in skeletal muscle whereas we found 
no effect of  testosterone on glycogen accumulation, as this has been shown 
before (149). The role of KLF10 in different diseases is unclear. 
Overexpression of KLF10 in liver leads to increased gluconeogenesis and to 
hyperinsulinemia (150). Furthermore, animal studies have shown that KLF10 
knockdown in hepatocytes lead to decreased glucose levels and improvement 
of glucose tolerance (151) . Next we investigated if the expression of KLF10, 
a transcriptional repressor regulating the circadian expression of genes 
involved in lipogenesis, gluconeogenesis, and glycolysis in liver (151), is 
regulated by insulin and/or testosterone in myotubes. Interestingly, insulin 
stimulation increased the mRNA expression of KLF10, a gene linked to 
conversion of glucose to glycogen in myotubes (152). Upregulation of KLF10 
in response to insulin in skeletal muscle of women with PCOS goes in line with 
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Figur 5. Schematic illustration of KLF10 activity in different tissues.       
Illustration: Igor Cervenka 
 
   
previous findings (153). Because we do not see an effect of testosterone on 
KLF10 expression, it suggests that hyperinsulinemia is a key factor in the 
regulation of this gene in PCOS. Further, as mentioned, KLF10 was 
upregulated in both adipose tissue and skeletal muscle in women with PCOS 
(Figure 5). 
 
 
 
 
 
 
 
 
 
 
 
It can be hypothesized that increased levels of androgen can have an indirect 
effect on aggravating hyperinsulinemia (154). This theory is supported by our 
findings from human muscle cell experiment where we showed that 
testosterone was involved in regulation of the gene expression of COL1A1 and 
MAP2K6. Furthermore, we found that changes in gene expression of these 
genes are under epigenetic control.    
We identified large number of genes that were altered in methylation and 
expression (paper I and II) and there are other interesting candidates that 
require further in-vitro and in-vivo studies in order to demonstrate that 
differential expression are related to low glucose infusion rate, increased 
testosterone levels and large adipocyte size in women with PCOS.  
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In general, we observed that gene expression changes are more pronounced 
than DNA methylation changes in both adipose tissue and skeletal muscle, 
which presumably is a result of interplay between other epigenetic and genetic 
mechanisms.  
The first challenge in running genome-wide methylation and gene expression 
arrays in all studies was to pre-process bioinformatics data an analyze 
Illuminas 450k BeadChip platform. We addressed problems with batch effect 
and removed the technical influence without removing the biological signal. 
The potential influence of technical effect on the biological results were 
avoided by running all genome-wide methylation and gene expression chips at 
the same time, and, by placing samples randomly on the cards. Furthermore, 
we have filtered out problematic probes such as the ones that have targeted the 
Y-chromosome. Methylation and gene expression data were scanned with 
probes. Therefore, we applied a method of quantile normalization in order to 
remove for unwanted technical variation. As expected, in paper I and II there 
was an effect of age and BMI on methylation data. Therefore, in all array 
analyses the corrections for age and BMI were made. 
Although the clinical studies were carefully designed, we have not taken into 
the account that different cell types can be confounding factor. Adipose tissue 
and skeletal muscle biopsies are composed of many different cell types. In our 
global methylation and gene expression studies, we used whole tissue biopsies 
to study methylome and transcriptome. Women with PCOS are often 
overweight and obese which leads to inflammation and it could explain why 
we identified genes involved in mediating inflammatory responses, such as IL6 
and CD74. In parallel to the publication of paper I, researchers from USA 
demonstrated that women with PCOS have methylation alterations in 
subcutaneous adipose tissue (79). However, results from these two studies are 
differing which might be due to the sample size and differential clinical 
characteristic between the two cohorts (76, 79). Surprisingly, we have not 
identified alterations in either INSR or LHCGR gene expression; however, both 
studies identified expression alterations in RAB5B. Furthermore, the other 
study found increased methylation of INSR in region that is largely 
unmethylated which explains decrease in gene expression. Furthermore, they 
have shown that genetic variations regulate methylation quantitative trait loci 
(meQTL) and expression quantitative trait loci (eQTL) suggesting that genetic 
variation regulates gene expression.    
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Effect of Electroacupuncture on whole-body glucose uptake and protein and 
gene expression  
We here demonstrate for the first time that a single bout of low-frequency 
electroacupuncture, via muscle contractions, increase whole-body glucose 
uptake in overweight and obese women with and without PCOS (study III). 
Single bout of low-frequency acupuncture also lowered adipose tissue 
expression of markers of sympathetic nerve activity: proNGF, serotonin and 
homovanillic acid.  Recently we established that five weeks of low-frequency 
electroacupuncture treatment improves HbA1c and lowers circulating and 
adipose tissue androgens, which might improve ovulation (155), indicating that 
it might be used in the clinic to assist muscle contractions and increase whole-
body glucose uptake. Furthermore, we have shown that electroacupuncture 
restores aberrant gene expressions in adipose tissue that were -identified in 
study I (76). In total, we found 80 genes including PPARγ, CD74 and 
ADIPOR2 to be restored to healthier phenotype by one single bout of 
electroacupuncture.  
PPARγ is a master regulator of adipocyte differentiation, and it controls the 
expression of many genes that are regulating different metabolic processes, it 
also have therapeutic application (156). In paper I we showed that there is a 
correlation between disturbances in methylation and transcriptomic changes in 
PPARγ in subcutaneous adipose tissue. We demonstrated that DNA 
methylation of PPARγ was increased and expression was downregulated by 
13.5 %, supporting the fact that increased methylation leads to downregulation 
of gene expression and, at least in part, contribute to the development of insulin 
resistance (76). Interestingly, one single bout of electroacupuncture decreased 
methylation marks in the body regions of PPARγ by 5.7% and increased the 
expression by 49.7%, which indicates that electroacupuncture exerts similar 
changes on PPARγ mRNA levels as exercise and can in part explains the 
increased glucose uptake measured by the clamp (157, 158).  
Next, we showed that major histocompatibility complex, class II invariant 
chain (CD74) is involved in the regulation of adipogenesis and inflammation 
(159). The expression of CD74 was increased in adipose tissue from women 
with PCOS, which might contribute to the unhealthy PCOS phenotype (76), 
and there was a positive correlation between gene expression and DNA 
methylation in CD74. Furthermore, we found gene expression of CD74 to 
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correlate positively with increased testosterone. In study IV, the CD74 gene 
was hypomethylated by 2.4%, and mRNA levels were decreased by ~23%, 
supporting the idea, that electroacupuncture may have the capacity to restore 
methylation alterations that could partly improve insulin sensitivity.  
Adipocyte size together with circulating adiponectin are the strongest factors 
explaining insulin resistance in women with PCOS (160). There is evidence 
that disruption of adiponectin and adiponectin signaling plays a role in 
pathogenesis of PCOS (161). Previous studies reported that mRNA expression 
of adiponectin receptor 2 (ADIPOR2) in women with PCOS is downregulated 
by hyperinsulinemia and overweight (162, 163). In our paper I was ADIPOR2 
downregulated by 12% in adipose tissue in women with PCOS in line with 
other studies (162).  In animal models of PCOS, the role of adiponectin has 
been shown to play an important role in protecting against increase in weight 
gain, insulin resistance and adipocyte hypertrophy (164). We demonstrate that 
electroacupuncture increases the ADIPOR2 mRNA expressions by 21% and 
therefore might be considered as an alternative treatment to improve glucose 
and lipid uptake via activation of adiponectin signaling.  
Because the positive effect of electroacupuncture have been demonstrated on 
several metabolic parameters e.g. HbA1c in women with PCOS we conducted 
a study where we aimed to elucidate the mechanism of action of 
electroacupuncture (165). As the effect of acupuncture has shown to be 
mediated via modulation of autonomic activity (among many factors) we 
decided to investigate the involvement of autonomy nervous system by 
administrating unselective adrenergic α and β-blockers, butaclamol and 
atropine during a euglycemic-hyperinsulinemic clamp and low-frequency 
electrical stimulation. We found that a single bout of electroacupuncture 
increases whole-body glucose uptake by activation of the sympathetic and 
partly the parasympathetic nervous systems, which could have important 
clinical implications for the treatment of insulin resistance. Next, we 
investigated if the expression of selected genes that changed by 
electroacupuncture was blocked when administrating alpha- and beta-
adrenergic blockers to rats during a euglycemic hyperinsulinemic clamp. 
Some animal studies showed that hyperinsulinemia exerts excitatory effect on 
sympathetic nervous system and might lead to elevated sympathetic output to 
other organs (166). However, high sympathetic nervous activity is measured 
in animal PCOS models, which is accompanied by elevated levels of nerve 
 35 
 
growth factor (NGF) that are involved with ovarian pathology (167). In an 
animal experiment, we have shown that electroacupuncture lowered the 
expression of Nr4a2 and Junb indicating that sympathetic nervous system in 
humans might mediates it signal via altering the gene expression of NR4A2 and 
JUNB. The biological function of NR4A4 in unknown and the role of JUNB 
(168) on adipogenesis remains to be elucidated. However, the nuclear receptor 
subfamily 4 (NR4A) has been associated with alterations in glucose utilization 
and oxidative phosphorylation in liver and skeletal muscle (169).  
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5 CONCLUSIONS AND FUTURE PERSPECTIVES  
Current studies on methylation in women with PCOS rely on microarrays in 
order to provide the information on methylation differences. The field of 
epigenetics is constantly advancing. With new emerging techniques 
approaching we will be able to make new discovers that will help to advance 
the knowledge of how epigenetic disturbances contribute to pathophysiology 
of PCOS.  
In the four studies of this thesis, we revealed that the methylation pattern of 
women with PCOS is altered in both adipose tissue and skeletal muscle and 
that the methylation mechanisms are involved in controlling the gene 
expression.  Furthermore, we show that one single bout of electroacupuncture 
induces rapid changes on methylome supporting the idea that epigenetic 
changes can by rapidly reversed by electroacupuncture in the similar way as 
exercise. The relationship between the two hallmarks of PCOS, 
hyperinsulinemia and hyperandrogenemia is still puzzling. Overall, our results 
point out that hyperinsulinemia is responsible for transcriptional changes on 
genes that are involved in regulating different metabolic processes. If the 
transcriptional changes are due to the epigenetic differences remains to be 
evaluated in the future studies. However, hyperinsulinemia may lead to 
increase in androgen concentration and furthermore to development of insulin 
resistance.  
The main conclusions of the papers are: 
Study I  Women with PCOS have genome-wide DNA methylation 
alterations that are associated with transcriptional changes in adipose tissue. 
Methylation changes correlate with gene expression changes in specific genes, 
which are associated with hyperandrogenemia, glucose homeostasis and 
increased adipocyte size.  
Study II  Women with PCOS have DNA methylation alterations that are 
associated with transcriptional changes in skeletal muscle. In human myotubes 
we demonstrated that mRNA expression levels are under hormonal regulation 
of insulin and testosterone.   
Study III  Single bout of low- frequency electroacupuncture increased 
whole-body glucose uptake in overweight and obese women with and without 
PCOS. Increased glucose uptake by electroacupuncture is mediated via 
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activation of the autonomic nervous system. Electroacupuncture lowers protein 
expression of markers of sympathetic nerve activity in plasma serotonin and 
homovanillic acid and a proNGF in adipose tissue. 
Study IV  Single bout of low-frequency electroacupuncture remodels 
genome-wide DNA methylation and gene expression changes in subcutaneous 
adipose tissue in women with PCOS. Changes in gene expression are mediated 
via activation of the sympathetic nervous system. Women with PCOS have 
increased levels of androgens in subcutaneous adipose tissue.  
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